MEGA Stock Overview
Manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Mega Lifesciences Public Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ฿33.75 |
| 52 Week High | ฿44.25 |
| 52 Week Low | ฿32.00 |
| Beta | 0.49 |
| 1 Month Change | -4.93% |
| 3 Month Change | -16.15% |
| 1 Year Change | -16.15% |
| 3 Year Change | -34.78% |
| 5 Year Change | 25.00% |
| Change since IPO | 58.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEGA | TH Pharmaceuticals | TH Market | |
|---|---|---|---|
| 7D | 1.5% | -1.2% | -4.7% |
| 1Y | -16.1% | 9.2% | -3.4% |
Return vs Industry: MEGA underperformed the TH Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: MEGA underperformed the TH Market which returned -3.4% over the past year.
Price Volatility
| MEGA volatility | |
|---|---|
| MEGA Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in TH Market | 8.9% |
| 10% least volatile stocks in TH Market | 2.1% |
Stable Share Price: MEGA has not had significant price volatility in the past 3 months compared to the TH market.
Volatility Over Time: MEGA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | n/a | Vivek Dhawan | www.megawecare.com |
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provides various medicines for allergies; blood circulation and memory; bone and joint; liver and digestive; eyes, heart, and skin; pain, sleeping, well-being, herbal, and cough and colds; and vitamins, probiotics, medical and sports nutrition, as well as kids’, men’s, and women’s care products.
Mega Lifesciences Public Company Limited Fundamentals Summary
| MEGA fundamental statistics | |
|---|---|
| Market cap | ฿29.43b |
| Earnings (TTM) | ฿1.85b |
| Revenue (TTM) | ฿15.88b |
15.9x
P/E Ratio1.9x
P/S RatioIs MEGA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEGA income statement (TTM) | |
|---|---|
| Revenue | ฿15.88b |
| Cost of Revenue | ฿8.14b |
| Gross Profit | ฿7.74b |
| Other Expenses | ฿5.90b |
| Earnings | ฿1.85b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.12 |
| Gross Margin | 48.74% |
| Net Profit Margin | 11.62% |
| Debt/Equity Ratio | 1.8% |
How did MEGA perform over the long term?
See historical performance and comparisonDividends
4.7%
Current Dividend Yield76%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 09:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mega Lifesciences Public Company Limited is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuwanee Prommaporn | BNP Paribas Securities (Asia) |
| Graham Price | CGS International |
| null null | DBS Bank Ltd |